• CCR7–Notch1 Crosstalk Drives Mammary Cancer Stemness

  2026-08-11

  Boyle et al. showed that CCR7 and Notch1 form a functional signaling circuit that sustains stem-like properties in MMTV-PyMT mammary cancer cells. The work provides a mechanistic basis for considering coordinated disruption of both axes, while its primary-cell mouse model also defines important limits for clinical translation.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-08-11

  The 2025 reference study identifies naturally occurring angiotensin fragments as modulators of SARS-CoV-2 spike-protein binding to host receptors, with the strongest effects associated with shorter peptides and tyrosine modification. Its antibody-based binding design provides a useful framework for connecting renin-angiotensin system research with viral-receptor biology while highlighting the need for cell-based and in vivo validation.

• NBC19: NLRP3 Inflammasome Inhibitor Workflows

  2026-08-10

  NBC19 enables controlled, dose-responsive interrogation of NLRP3-driven IL-1β release in differentiated THP1 cells. This practical guide connects benchmark Nigericin and ATP assays with cancer-inflammation models, including exploratory studies of circulating macrophage-like giant cells.

• Sitagliptin Phosphate Monohydrate in Translation

  2026-08-09

  Sitagliptin phosphate monohydrate offers a precise way to interrogate DPP-4, incretin biology, and metabolic state. By connecting peptide preservation with new evidence on intestinal stretch, this article outlines a translational framework for stronger metabolic and vascular research designs.

• Drug-Sensitized Yeast for mTOR Inhibitor Discovery

  2026-08-08

  Breen and colleagues developed a genetically engineered, drug-sensitized yeast platform that detects TOR pathway inhibitors at substantially lower concentrations than wild-type yeast. The system distinguishes TOR-dependent growth effects and provides a practical screening framework, while its negative result for Canagliflozin illustrates why pathway-specific validation is essential in metabolic research.

• FLAG tag Peptide (DYKDDDDK): Uses & Limits

  2026-08-07

  The FLAG tag Peptide is the eight-residue DYKDDDDK epitope used for recombinant protein detection and affinity purification. Its defined composition, high reported solubility, and compatibility with anti-FLAG M1 and M2 affinity resin elution support reproducible workflows, while its inability to elute 3X FLAG fusions defines an important boundary.

• Recombinant Human Oncostatin M: Mechanistic Insights & Preci

  2026-08-07

  Explore how Recombinant Human Oncostatin M (rh-Oncostatin M) enables advanced, mechanistically informed cytokine stimulation of fibroblast proliferation and beyond. This article uniquely bridges molecular action, protocol precision, and the latest reference findings for next-generation research.

• AG-221 (Enasidenib): Deep Mechanistic Insights & Practical P

  2026-08-06

  Explore the advanced mechanism and practical assay considerations of AG-221 (Enasidenib) in acute myeloid leukemia research. This article delivers a unique, science-driven perspective on metabolic rewiring, resistance, and optimal experimental use, setting it apart from existing content.

• SMAD3 Inhibition Lowers ADAMTS-5 via miRNA-140 in Early Oste

  2026-08-06

  Xiang et al. demonstrate that pharmacological inhibition of SMAD3 suppresses ADAMTS-5 expression in early osteoarthritis, likely through upregulation of miRNA-140. This mechanistic insight offers a targeted approach for dissecting TGF-β/Smad signaling in cartilage degeneration models and highlights new avenues for fibrosis research.

• PF-04971729 (Ertugliflozin): Advanced Workflows in Diabetes

  2026-08-05

  Ertugliflozin (PF-04971729) redefines experimental precision in diabetes mellitus and neurodegeneration research. This guide delivers actionable protocol enhancements, real-world troubleshooting, and novel use-cases that set APExBIO's high-purity offering apart for SGLT2-mediated glucose transport studies.

• Anagliptin Induces Vasorelaxation via Kv Channel and SERCA A

  2026-08-05

  The referenced Acta Diabetologica study demonstrates that anagliptin (SK-0403), a DPP-4 inhibitor, directly induces vasorelaxation in rabbit aorta by activating voltage-dependent K+ (Kv) channels and the SERCA pump. These findings clarify the vascular actions of anagliptin, informing research on cardiovascular safety in diabetes therapies and supporting protocol development for vascular pharmacology studies.

• Protein A/G Magnetic Beads: Accelerating Translational Prote

  2026-08-04

  Explore how Protein A/G Magnetic Beads empower translational researchers to dissect complex protein interactions in disease models, with mechanistic insight and actionable strategies for immunoprecipitation-based discovery. Bridging the latest molecular findings in degenerative disease with advanced bead technology, this article provides protocol guidance, competitive context, and a forward-looking perspective on precision affinity workflows.

• SP2509 as a Lysine-Specific Demethylase 1 Antagonist: Applie

  2026-08-04

  SP2509 empowers researchers to interrogate cancer epigenetics with precision, offering robust, reproducible modulation of LSD1 activity in AML and beyond. This guide delivers step-by-step protocols, protocol-optimizing insights, and troubleshooting support for leveraging SP2509’s full potential in applied bench research.

• Mavorixafor Hydrochloride: Strategic Insights for Translatio

  2026-08-03

  This thought-leadership article explores the mechanistic underpinnings and translational utility of Mavorixafor hydrochloride (AMD-070 hydrochloride) as a potent and selective CXCR4 antagonist. We integrate foundational research, clinical perspectives, and pragmatic protocol guidance to empower biomedical innovators targeting the CXCR4/CXCL12 axis in immunology, hematology, and virology, especially anti-HIV research. By bridging experimental rigor with strategic foresight and directly referencing both legacy and contemporary findings, this piece delivers actionable intelligence for researchers seeking to leverage Mavorixafor hydrochloride in next-generation studies.

• 3-Aminobenzamide (PARP-IN-1): Precision PARP Inhibition for

  2026-08-03

  3-Aminobenzamide (PARP-IN-1) empowers researchers to dissect poly (ADP-ribose) polymerase pathways across cardiovascular, immunometabolic, and viral systems, offering low-toxicity, high-selectivity inhibition. This article details optimized workflows, cross-domain applications, and troubleshooting strategies that set APExBIO’s 3-Aminobenzamide apart for advanced experimental design.

16109 records 1/1074 page Next 12345 下5页 Last page